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Abstract
Background: We evaluated the psychometric characteristics of the Short Form 36 (SF-36) Health Survey and the
Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue subscale in patients with ankylosing spondylitis
(AS).
Methods: We analyzed clinical and patient-reported outcome (PRO) data collected during 12-week, double-blind,
placebo-controlled periods of two randomized controlled trials comparing adalimumab and placebo for the
treatment of active AS. The Bath Ankylosing Spondylitis Disease Activity Index, Bath Ankylosing Spondylitis
Functional Index, and other clinical measures were collected during the clinical trial. We evaluated internal
consistency/reliability, construct validity, and responsiveness to change for the SF-36 and FACIT-Fatigue.
Results: The SF-36 (Cronbach alpha, 0.74-0.92) and FACIT-Fatigue (Cronbach alpha, 0.82-0.86) both had good
internal consistency/reliability. At baseline, SF-36 and FACIT-Fatigue scores correlated significantly with Ankylosing
Spondylitis Quality of Life scores (r = -0.36 to -0.66 and r = -0.70, respectively; all p < 0.0001). SF-36 scores varied
by indicators of clinical severity, with greater impairment observed for more severe degrees of clinical activity (all p
< 0.0001). FACIT-Fatigue scores correlated significantly with SF-36 scores (r = 0.42 to 0.74; all p < 0.0001) and varied
by clinical severity (p < 0.05 to p < 0.0001).
Conclusions: The SF-36 is a reliable, valid, and responsive measure of health-related quality of life and the FACIT-
Fatigue is a brief and psychometrically sound measure of the effects of fatigue on patients with AS. These PROs
may be useful in evaluating effectiveness of new treatments for AS.
Trial Registration: ClinicalTrials.gov: NCT00085644 and NCT00195819
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Background
Ankylosing spondylitis (AS) is a chronic and progressive
inflammatory disorder that primarily affects the axial
skeleton, sacroiliac joints of the pelvis, and thoracic cage
[1,2]. Patients experience pain, joint stiffness, and the
eventual loss of spinal mobility with disease progression.
Patients with AS frequently experience impaired physi-
cal function and well-being, require time away from
work because of disability, and suffer from diminished
health-related quality of life (HRQOL) [3-7]. The impact
of AS on functioning and everyday life varies by patient,
but most patients typically have a broad spectrum of
impairments, including the physical, psychological, and
social domains of HRQOL.
Patient-reported outcomes (PROs), including HRQOL
assessments, symptom scales, and other measures, are
increasingly used to evaluate the health-related out-
comes of rheumatology treatments from the patient per-
spective. PROs are incorporated into clinical studies of
patients with AS and provide important assessments of
functioning and well-being that complement and expand
* Correspondence: dennis.revicki@unitedbiosource.com
1Outcomes Research, United BioSource Corporation, Bethesda, MD, USA
Full list of author information is available at the end of the article
Revicki et al. Health and Quality of Life Outcomes 2011, 9:36
http://www.hqlo.com/content/9/1/36
© 2011 Revicki et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.on traditional clinical outcomes in AS [8]. AS impacts
multiple HRQOL domains [6], including pain, physical
function, fatigue, and psychological well-being [3,4,7-10].
Therefore, assessing HRQOL outcomes is important for
a comprehensive understanding of the effectiveness of
new treatments for AS. HRQOL outcome results from
randomized controlled clinical trials permit physicians
and patients to better understand and compare the
health benefits of various therapies for AS.
Although disease-specific HRQL measures, such as the
AS Quality of Life (ASQoL) Questionnaire, may be
more sensitive to treatment effects and changes in clini-
cal status, generic HRQL measures are useful for evalu-
ating the burden of disease and for normative
comparisons with general population samples. Generic
HRQL measures, such as the Short Form 36 (SF-36)
Health Survey, have been used to document the impact
of chronic diseases on patient functioning and well-
being, including AS [4]. Given the availability of general
population samples, these generic HRQL measures can
also be used for normative comparisons with chronic
disease groups, such as AS, which can help interpret
changes in HRQL related to treatment or disease pro-
gression. Fatigue is associated with rheumatoid arthritis
and AS [3,4,6-10], and generic measures of fatigue may
assist clinicians in understanding the experience of
patients with AS.
Several PRO measures have been used in studies of
patients with AS [8,11]. These measures include the
SF-36 Health Survey [12,13]; the AS Quality of Life
Questionnaire [14,15]; and the Revised Leeds Disability
Questionnaire [16]. For application in clinical trials, it
is necessary to demonstrate a measure’s reliability,
construct validity, and responsiveness [17,18]. The SF-
36 has been used in several studies of patients with AS
[12,19-22]. The developers of the ASQoL provided evi-
dence supporting the reliability and validity of the
measure [14,15]. However, additional information is
needed to confirm the psychometric qualities of the
SF-36 in AS.
The objective of the current analysis was to evaluate
the psychometric characteristics of two PRO measures –
the SF-36 Health Survey and the Functional Assessment
of Chronic Illness Therapy (FACIT)-Fatigue subscale –
in a sample of patients with AS. The psychometric char-
acteristics examined included internal consistency/relia-
bility, construct validity, and responsiveness to changes
in patients’ clinical disease activities. The current ana-
lyses are based on data from two completed clinical
trials of adalimumab in patients with active AS [23,24].
Evidence supporting the psychometric characteristics of
PROs is necessary for clinical trial analyses that compare
treatments to support claims of HRQOL benefit [18].
Methods
Study design and patients
These psychometric analyses were completed based on
clinical and PRO data collected from two Phase III, ran-
domized, double-blind, placebo-controlled clinical trials
that assessed the safety and clinical efficacy of subcuta-
neous injections of adalimumab in patients with AS.
The two clinical trials – the Adalimumab Trial Evaluat-
ing Long-Term Efficacy and Safety in Ankylosing Spon-
dylitis (ATLAS) [23-25] and the M03-606 study [26] –
were similar in research design. ATLAS was completed
in 43 centers in the United States and Europe (Clinical-
Trials.gov identifier, NCT00085644), and the M03-606
study was conducted in 11 clinical centers in Canada
(ClinicalTrials.gov identifier, NCT00195819).
Briefly, patients were 18 years of age or older with a
diagnosis of AS according to the Modified New York
criteria [27]. Patients also had to exhibit active disease,
defined as meeting at least two of the following three
conditions: Bath AS Disease Activity Index (BASDAI)
score ≥4 (0-10-cm scale); total back pain score ≥4o na
0-10-cm visual analog scale (VAS); or morning stiffness
≥1 hour. Inclusion criteria included an inadequate
response to or intolerance of one or more nonsteroidal
anti-inflammatory drugs or disease modifying antirheu-
matic drugs and a willingness to self-administer subcu-
taneous injections of adalimumab (HUMIRA
®; Abbott
Laboratories, Abbott Park, IL, USA) or matching pla-
cebo. Patients with radiologic evidence of total spinal
ankylosis (bamboo spine) were excluded from participa-
tion in the M03-606 study, and enrollment of patients
with total spinal ankylosis in ATLAS was limited to
≤10% of the total study sample.
In both studies, eligible patients were randomized to
receive adalimumab 40 mg every other week or placebo
for the initial 12-week, double-blind period of each
study. The psychometric analyses described here were
not designed to evaluate the treatment effects of adali-
mumab compared with placebo. This report describes
only the methods and results of a blinded evaluation of
the psychometric qualities of selected PROs assessed
during the initial 12-week period of both clinical trials.
Institutional review boards at participating clinical cen-
ters approved the protocol and all patients provided
voluntary, written informed consent. Both studies were
conducted in accordance with the Declaration of
Helsinki.
Patient-reported outcomes
Three PRO measures were included in this psycho-
metric evaluation study: theS F - 3 6H e a l t hS u r v e y ,t h e
FACIT-Fatigue scale, and the ASQoL. The SF-36 and
ASQoL were included in both ATLAS and the M03-606
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disease-specific (ASQoL) and generic (SF-36) domains
of HRQOL. The FACIT-Fatigue was employed only in
M03-606, and was selected to evaluate the impact of AS
treatment on fatigue outcomes, as previous studies have
demonstrated treatment effects on fatigue in patients
with rheumatoid arthritis [28] and AS [23]. For the
ASQoL and FACIT-Fatigue, data were collected at base-
line, Week 2, and Week 12; the SF-36 was completed
only at baseline and Week 12. The ASQoL was included
to evaluate the construct validity of the other PRO
measures.
Ankylosing Spondylitis Quality of Life Questionnaire
The ASQoL is a disease-specific instrument designed to
measure quality of life in patients with AS and was
developed using a needs-based model [15]. The instru-
ment contains 18 yes or no items on the impact of AS
“at this moment.” The ASQoL has a total score ranging
from 0 to 18, with lower scores representing better AS-
specific quality of life. The instrument has good reliabil-
ity and construct validity across several different AS
populations [8,14,15,22].
Functional Assessment of Chronic Illness Therapy (FACIT)-
Fatigue Subscale
The FACIT-Fatigue is a frequently used instrument that
measures fatigue and its effect on functioning and daily
activities [28]. The FACIT-Fatigue has 13 items
answered on a 5-point rating scale based on a 7-day
recall period. Scores range from 0 to 52, with lower
scores reflecting greater fatigue. The instrument has
good reliability and validity based on analyses of the
general population in the United States, patients with
cancer, and patients with rheumatoid arthritis [28-30],
but a search of the medical literature indicated no pub-
lished data on the psychometric qualities of the FACIT-
Fatigue in AS patients.
Short Form 36 Health Survey
The SF-36 Health Survey is a generic health status
instrument developed for application in primary care
and chronic disease populations [13]. The SF-36 Version
1, with a 4-week recall period, was used in this study.
The SF-36 contains two summary scores (Mental Com-
ponent Summary [MCS] and Physical Component Sum-
mary [PCS] scores), and the following eight subscales:
physical function, bodily pain, role-physical, general
health, vitality, social function, role-emotional, and men-
tal health. The SF-36 subscales and summary scores
have excellent reliability and good construct validity
across the general US population and chronic disease
populations [13,31], including in patients with AS
[4,19-22,32,33].
Bath Ankylosing Spondylitis Disease Activity
The BASDAI is a six-item measure of disease activity
and includes questions on fatigue, spinal pain, peripheral
arthritis, enthesitis (i.e., inflammation at the attachment
of ligaments or tendons to bone), and morning stiffness
[34]. The BASDAI is a well-established instrument
widely used in clinical studies to evaluate AS disease
activity. All items are patient reported using a 0-10
VAS, and lower scores indicate less disease activity.
Bath Ankylosing Spondylitis Functional Index
The BASFI consists of 10 questions related to daily
activities. The original BASFI used a 0 to 10 VAS for
each of the 10 questions, for which 0 indicates that an
activity was performed without difficulty and 10 indi-
cates that an activity was impossible to perform. The
mean of these yields the final BASFI score of 0-10 [35].
However, in ATLAS and the M03-606 study, patients
answered each of the same 10 questions using a 0-100-
mm VAS, and the mean gave a final BASFI score of 0-
100.
Clinical measures
The Assessment of SpondyloArthritis international
Society (ASAS) [36] was used in these psychometric
analyses. The ASAS response criterion [36] consists of
the percentage of improvement in three of the following
four domains: patient’s global assessment of disease
activity VAS, pain, function (represented as the mean
BASFI score [35]), and inflammation (represented as the
mean of the two morning stiffness-related BASDAI
questions). The ASAS 20% improvement (ASAS20),
ASAS50, and ASAS70 response criteria were used in the
clinical trials and have been applied by regulatory agen-
cies to evaluate the clinical efficacy of tumor necrosis
factor (TNF) antagonists for the treatment of AS. For
the psychometric analyses based on ASAS response cri-
teria, patients were categorized into mutually exclusive
groups corresponding to at least ASAS20, at least
ASAS50, or at least ASAS70 response criteria based on
the Week 12 assessment.
Statistical analyses
The psychometric qualities of the PROs were assessed
to determine reliability, validity, and responsiveness
[17,37]. The internal consistency/reliability of the multi-
item instruments and subscales was evaluated using the
Cronbach alpha coefficient [38]. Reliabilities were esti-
mated at baseline and at Week 12. A Cronbach alpha
coefficient of > 0.70 was indicative of acceptable internal
consistency/reliability of group comparisons [17]. We
examined the item-total correlations (corrected for over-
lap) as another indicator of reliability for the SF-36 sub-
scales and FACIT-Fatigue. In addition, we replicated the
factor analysis of the SF-36 subscales to verify the factor
structure underlying the PCS and MCS scores.
Validity reflects the extent to which an instrument or
subscale actually measures the construct it is intended
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specifying and testing hypotheses about the relationships
between the measures and clinical assessments or other
PRO measures. We evaluated the relationship between
SF-36 scores and FACIT-Fatigue scores and selected
clinical measures (specifically the BASDAI total score,
the BASDAI fatigue question, the BASDAI pain ques-
tion, total back pain, BASFI, patient’s global assessment
of disease activity, and the physician’sg l o b a la s s e s s m e n t
of disease activity). We hypothesized that the BASDAI,
BASFI, BASDAI fatigue question, and patient global
assessment of disease activity would have moderate to
strong (0.40-0.60) correlations with the FACIT-Fatigue,
and SF-36 PCS scores, while the pain and physician glo-
bal measures would have moderate to strong correla-
tions with the SF-36 PCS, and low to moderate (0.20-
0.40) correlations with FACIT-Fatigue. We consider cor-
relations < 0.30 to be low; correlations 0.30 to 0.60 to be
moderate; and correlations > 0.60 to be strong. In addi-
tion, we examined the relationships between the
FACIT-Fatigue and SF-36 subscales and summary scores
and the ASQoL scores. Pearson’s correlation coefficients
were used to evaluate the strength and direction of
these associations at baseline and at Week 12.
Analysis of covariance (ANCOVA) models, with
adjustment for age and sex, were used to evaluate mean
PRO scores by clinical severity based on total BASDAI
score (≥7, 4-6.9, or < 4), BASDAI fatigue score (≥7, 4-
6.9, or < 4), BASDAI pain score (≥7, 4-6.9, or < 4), pain
score (≥66, 34-65, or < 34), total back pain score (≥66,
34-65, or < 34), BASFI score (≥66, 34-65, or < 34), and
patient’s and physician’s global assessments of disease
activity (≥66 vs. < 66). These categories were defined
through review of sample distributions and designed to
divide patients roughly into groups representing severe,
moderate, and mild disease.
The responsiveness of the FACIT-Fatigue and SF-36
subscales and summary scores was evaluated by deter-
mining the association between the ASAS and the
PRO measures. ANCOVA models were used to esti-
mate least-square mean baseline to 12-week change
scores for the SF-36 subscales, as well as the PCS,
MCS, and FACIT-Fatigue scores. The ANCOVA mod-
els included factors for the ASAS response group (i.e.
<2 0 % ;≥20% to < 50%; ≥50% to < 70%; and ≥70%),
age, sex, and the relevant baseline PRO score. The
clinical responsiveness analyses focused on the baseline
to 12-week changes in the clinical and PRO measures.
Effect-size estimates were also included for interpreta-
tion purposes.
All statistical tests were based on an alpha of 0.05,
with no adjustments for multiple statistical tests. The
results were interpreted with consideration for the num-
ber of statistical analyses performed.
Results
ATLAS enrolled 315 patients and the M03-606 study
enrolled 82 patients. The average age of patients with
AS who participated in the two clinical trials was 42.0
years (SD, 11.5), and the sample was mostly male
(75.8%) and white (95.7%) (Table 1). At baseline, the
mean BASFI score was 53.9 (SD, 21.9), the mean BAS-
DAI score was 6.3 (SD, 1.7), and the mean ASQoL
score was 10.5 (SD, 4.3). The average duration of AS
was 11.3 years (SD, 9.4).
Patient-reported outcome descriptive statistics and
reliability
Complete baseline and Week 12 data were available for
98.2% of patients in the two clinical trials. The baseline
means, standard deviations, and internal consistency/
reliability coefficients for the FACIT-Fatigue and SF-36
subscale scores are summarized in Table 2. The internal
consistency/reliability coefficients for the FACIT-Fatigue
were 0.82 at baseline and 0.86 at Week 12. All reliability
coefficients for the SF-36 subscales exceeded 0.75 at
both baseline and Week 12, except for general health at
baseline (0.74) (Table 2). For the FACIT-Fatigue, item-
total correlations were 0.56-0.88 for both visits. At base-
line, item-total correlations for the SF-36 subscales were
0.35-0.74 for physical function; 0.49-0.61 for role-
Table 1 Baseline demographic and clinical characteristics
(N = 397)
Characteristic
a
Age, years 42.0
(11.5)
Sex, n (%)
Female 96 (24.2)
Male 301 (75.8)
Race, n (%)
White 380 (95.7)
Non-white 17 (4.3)
HLA-B27, n (%)
Negative 74 (18.9)
Positive 317 (81.1)
Duration of AS, years 11.3 (9.4)
Patient’s global assessment of disease activity, 0-100-mm
VAS
64.2
(20.7)
BASFI, 0-100 VAS 53.9
(21.9)
Inflammation, 0-100-mm VAS 67.7
(20.2)
Total back pain, 0-100-mm VAS 66.2
(20.2)
BASDAI, 0-10-cm VAS 6.3 (1.7)
C-reactive protein, mg/dL 1.9 (2.4)
a Data are mean (SD) unless otherwise noted.
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health; 0.57-0.64 for vitality; both 0.68 for social func-
tion; 0.59-0.72 for role-emotional; and 0.55-0.77 for
mental health. The item-total correlations for the SF-36
domain scores were comparable at 12 weeks (data not
shown). We replicated the factor analysis of the SF-36
subscale scores and found a comparable factor structure
to that reported by Ware et al. [13] (data not shown).
Relationships between patient-reported outcomes
The correlations between the ASQoL and the FACIT-
Fatigue were -0.70 (p < 0.0001) at baseline and -0.81 (p
< 0.0001) at Week 12. Correlations between the ASQoL,
FACIT-Fatigue, and SF-36 subscales and summary
scores are reported in Table 3. ASQoL scores were sig-
nificantly correlated with SF-36 summary scores at both
baseline and Week 12 (p < 0.0001), with the greatest
baseline correlations between the ASQoL and social
function (r = -0.66, p < 0.0001), bodily pain (r = -0.60, p
< 0.0001), and physical function (r = -0.59, p < 0.0001).
The Week 12 correlations were greater than the baseline
correlations (Table 3).
FACIT-Fatigue scale scores were significantly corre-
lated with SF-36 subscale scores at baseline and at 12
weeks (Table 3). The greatest correlations were between
the FACIT-Fatigue score and the SF-36 vitality subscale
score (r = 0.74 at baseline and 0.82 at Week 12, both p
< 0.0001). FACIT-Fatigue scores were also well-corre-
lated at baseline with social function (r =0 . 6 7 ,p<
0.0001), physical function (r = 0.58, p < 0.0001), and
bodily pain (r = 0.56, p < 0.0001). The correlations for
the Week 12 scores were similar but greater. The PCS
and MCS scores were both significantly correlated with
FACIT-Fatigue scores at baseline (r = 0.54 and r = 0.53,
respectively, both p < 0.0001) and Week 12 (r = 0.63
and r = 0.71, respectively, both p < 0.0001).
Relationships between patient-reported outcomes and
clinical measures
FACIT-Fatigue scores were correlated with all of the
selected clinical outcome measures (Table 4). The
FACIT-Fatigue was most substantially correlated with
the BASDAI fatigue item (r = -0.69, P < 0.0001), the
BASDAI (r = -0.60, p < 0.0001), and the BASFI (r =
-0.56, p < 0.0001). For the SF-36, the greatest correla-
tions were observed between the clinical assessments
and the physical function (r =- 0 . 3 6t or =- 0 . 7 2 ,a l lp<
0.0001) and bodily pain subscale scores (r =- 0 . 4 2t or =
-0.64, all p < 0.0001). In general, the PCS was more sub-
stantially correlated with the clinical outcome measures
than the MCS (Table 4). The BASDAI was significantly
correlated with the PCS (r = -0.47, p < 0.0001) and
MCS (r = -0.22, p < 0.0001). The BASFI was more
strongly correlated with the PCS (r = -0.65, p < 0.0001)
than the MCS (r = -0.15, p < 0.05).
Table 2 Baseline descriptive statistics and internal consistency reliability coefficients for patient-reported outcomes
Patient-reported outcome measure N Mean (SD) Internal consistency reliability
a
Baseline Week 12
FACIT-Fatigue 82 24.0 (10.2) 0.82 0.86
SF-36
Physical function 396 47.8 (22.0) 0.87 0.92
Role-physical 397 19.3 (29.3) 0.76 0.84
Bodily pain 397 31.0 (15.8) 0.77 0.89
General health 396 42.2 (20.0) 0.74 0.78
Vitality 397 33.0 (17.6) 0.78 0.88
Social function 397 54.9 (24.2) 0.80 0.84
Role-emotional 395 52.2 (42.6) 0.82 0.83
Mental health 397 62.2 (18.7) 0.83 0.87
a Cronbach alpha.
Table 3 Relationship between ASQOL, FACIT-Fatigue, and
SF-36 subscales and summary scores
a
SF-36 scores Baseline Week 12
ASQoL FACIT-F ASQoL FACIT-F
Physical function -0.59 0.58 -0.73 0.64
Role-physical -0.50 0.53 -0.73 0.65
Bodily pain -0.60 0.56 -0.76 0.75
General health -0.49 0.50 -0.65 0.57
Vitality -0.53 0.74 -0.72 0.82
Social function -0.66 0.67 -0.77 0.73
Role-emotional -0.39 0.42 -0.64 0.61
Mental health -0.53 0.42 -0.67 0.64
Physical Component Summary
(PCS)
-0.50 0.54 -0.70 0.63
Mental Component Summary
(MCS)
-0.51 0.53 -0.65 0.71
a p < 0.0001 for all correlations.
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used to evaluate the association between clinical severity
and the PRO measures (Table 5). For the FACIT-Fati-
gue, there were statistically significant differences in
mean scores by BASDAI (p < 0.0001), BASDAI fatigue
(p < 0.0001), BASDAI pain (p = 0.0002), total back pain
(p = 0.013), and BASFI (p < 0.0001). As clinical severity
increased, mean FACIT-Fatigue scores decreased (i.e.
worse fatigue symptoms). For example, for the BASDAI
fatigue item, mean FACIT-Fatigue scores were least for
those patients in the most severe group compared with
the less severe groups (Table 5). Similar patterns of
mean FACIT-Fatigue scores were observed for the other
clinical severity measures. Patients who rated their dis-
ease activities ≥66 had mean FACIT-Fatigue scores of
20.4 compared with those who rated their disease activ-
ities <66 (mean FACIT-Fatigue, 29.5) (p < 0.0001, Figure
1).
We also compared mean PCS and MCS scores by the
clinical severity measures (Table 5). For the PCS, there
were statistically significant differences in mean scores
by BASDAI, BASDAI fatigue, BASDAI pain, total back
pain, and BASFI (all p < 0.0001). In all cases, mean PCS
scores were worse (i.e. lower indicating impaired physi-
cal health status) for those patients reporting greater
clinical severities. Mean PCS scores varied significantly
by patient’s and physician’s global assessments of disease
severity (p < 0.0001, Figure 2). For the MCS, there were
statistically significant differences in mean scores by
BASDAI (p = 0.0003), BASDAI fatigue (p < 0.0001), and
B A S F I( p=0 . 0 2 8 ) ,b u tn o tf o rB A S D A Ip a i n( p=
0.289), total back pain (p = 0.076), or the physician’s
global assessment (p = 0.750). The mean MCS scores
were generally better for patients reporting lower clinical
severity of symptoms. For example, for BASDAI fatigue,
MCS scores were most impaired for the most severe
group (mean BASDAI fatigue, 40.2), less impaired for
the moderate group (mean BASDAI fatigue, 45.9), and
best for the mild group (mean BASDAI fatigue, 48.9).
Mean MCS scores varied significantly by patient’s global
ratings (p = 0.021) but not the physician’sg l o b a la s s e s s -
ment of disease (data not shown).
Responsiveness of patient-reported outcomes
Clinical responsiveness was evaluated by determining
the relationships between mean baseline to Week 12
changes in FACIT-Fatigue and SF-36 scores by ASAS
response criteria (i.e. non-responders and 20%, 50%, or
70% responders). The ASAS responder groups achieved
statistically significant improvements in FACIT-Fatigue
scores compared with the nonresponder group (p <
0.0001). Differences in mean baseline to 12-week change
scores between the nonresponder group and the respon-
der groups were 9.7 points for ASAS20, 14.6 points for
ASAS50, and 15.4 points for ASAS70 (Table 6). FACIT-
Fatigue change scores for patients meeting ASAS70
response criteria were fairly similar to those meeting
ASAS50 response criteria.
There were statistically significant differences in mean
baseline to 12-week changes in PCS scores between the
ASAS responder groups (p < 0.0001, Table 6). After 12
weeks of treatment, mean change scores from baseline
for SF-36 PCS scores were significantly greater for
patients who responded to therapy compared with those
who did not respond to therapy (p < 0.001). Changes in
SF-36 PCS scores were lowest for ASAS nonresponders
Table 4 Relationship between patient-reported outcome and clinical measures
a
Patient-reported
outcome measure
Clinical outcome measures
BASDAI BASDAI
fatigue
BASDAI
pain
Total
back pain
BASFI Patient’s global assessment of
disease severity
Physician’s global assessment
of disease severity
FACIT-Fatigue -0.60 -0.69 -0.47 -0.27 -0.56 -0.41 -0.25
SF-36
Physical function -0.45 -0.36 -0.40 -0.41 -0.72 -0.46 -0.36
Role-physical -0.37 -0.32 -0.29 -0.37 -0.40 -0.42 -0.29
Bodily pain -0.58 -0.45 -0.55 -0.55 -0.57 -0.64 -0.42
General health -0.31 -0.30 -0.25 -0.20 -0.38 -0.30 -0.31
Vitality -0.35 -0.49 -0.21 -0.24 -0.33 -0.30 -0.10
a
Social function -0.38 -0.41 -0.25 -0.30 -0.42 -0.37 -0.24
Role-emotional -0.22 -0.22 -0.16
a -0.16
a -0.19
a -0.20 -0.18
a
Mental health -0.24 -0.27 -0.15
a -0.12
a -0.21 -0.18
a -0.10
a
PCS -0.47 -0.36 -0.43 -0.46 -0.65 -0.52 -0.40
MCS -0.22 -0.30 -0.11
a -0.11
a -0.15
a -0.16
a -0.10
a
a p < 0.001 for correlations indicated.
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the ASAS50 responders were almost double the changes
for the ASAS20 responders, and mean changes in the
ASAS70 responders were more than double the changes
in the ASAS20 responders.
There were also statistically significant differences in
mean baseline to Week 12 MCS scores across different
ASAS responder groups (p < 0.0001, Table 6). The
baseline to 12-week change scores for patients achiev-
ing the ASAS20 and ASAS70 response criteria were
2.8 and 9.1 points greater, respectively, compared with
non-responders (p < 0.0001). The ASAS50 responders
actually had mean change scores that were less than
those of ASAS20 responders, but greater than those of
nonresponders.
We compared the mean baseline to Week 12 changes
in the SF-36 subscale scores by ASAS responder status
(Table 6). There were statistically significant
Table 5 Relationship between clinical severity and
selected patient-reported outcomes
Clinical Severity
Measure
Patient-reported outcome measure
FACIT-Fatigue Mean
(SE)
PCS
Mean
(SE)
MCS
Mean
(SE)
BASDAI, 0-10 VAS
≥7 17.55 (1.64) 29.25
(0.57)
40.23
(1.01)
4 to 6.9 26.08 (1.26) 33.22
(0.50)
45.19
(0.69)
<4 37.86 (2.32) 40.77
(1.25)
45.29
(1.88)
p-value < 0.0001 < 0.0001 = 0.0003
BASDAI fatigue, 0-10
VAS
≥7 18.50 (1.30) 30.27
(0.49)
40.20
(0.78)
4 to 6.9 27.24 (1.58) 34.09
(0.65)
45.95
(0.84)
< 4 36.18 (1.24) 37.95
(1.24)
48.94
(1.70)
p-value < 0.0001 < 0.0001 < 0.0001
BASDAI pain, 0-10 VAS
≥7 20.47 (1.39) 30.20
(0.45)
42.56
(0.76)
4 to 6.9 29.14 (1.64) 35.71
(0.68)
45.41
(0.88)
< 4 29.25 (4.50) 39.66
(1.65)
41.23
(2.20)
p-value = 0.0002 < 0.0001 = 0.298
Total back pain, 0-100
VAS
≥66 21.60 (1.46) 30.00
(0.47)
42.71
(0.78)
34 to 65 27.99 (1.65) 35.29
(0.65)
43.78
(0.91)
< 34 24.00 (8.00) 38.98
(1.33)
46.60
(1.90)
p-value = 0.013 < 0.0001 = 0.076
BASFI, 0-100 VAS
≥66 17.63 (1.60) 26.83
(0.47)
41.57
(1.10)
34 to 65 24.88 (1.45) 33.45
(0.48)
44.06
(0.79)
< 34 33.62 (2.19) 39.51
(1.78)
44.77
(1.14)
p-value < 0.0001 < 0.0001 = 0.028
Figure 1 FACIT-Fatigue Scores by Disease Activity.M e a n( S E )
Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue
subscale scores by patient’s and physician’s global assessment of
disease activity.
Figure 2 SF-36 PCS Scores by Disease Activity.M e a n( S E )S F - 3 6
Physical Component Summary (PCS) scores by patient’s and
physician’s global assessments of disease activity.
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Page 7 of 11improvements in all of the SF-36 subscale scores
between non-responder and responder groups (all p <
0.0001). For example, for SF-36 physical function scores,
we observed a 14.3-point improvement in the ASAS20
responder group, a 16.8-point improvement in the
ASAS50 responder group, and a 24.9-point improve-
ment in the ASAS70 responder group, all compared
with the non-responder group. These differences in
mean change scores were seen across most of the SF-36
subscales, except for mental health and social function,
with the greatest effects observed in the ASAS50 and
ASAS70 responder groups.
Discussion
Patient-reported outcomes, such as HRQOL, functional
status, and fatigue measures, are increasingly used to
examine the effectiveness of new therapies for AS
[19,23,39-42], but there is little documentation as to the
Table 6 Baseline to Week 12 mean changes in patient-reported outcomes according to ASAS working group response
criteria
Patient-reported outcome measure ASAS Response ASAS Response ASAS Response ASAS Response p-value
Nonresponder ASAS20 ASAS50 ASAS70
Mean change from baseline to Week 12 (SE)
Effect Size (ES)
FACIT-Fatigue -0.24 (0.95) 9.42 (1.24) 14.33 (1.89) 15.20 (2.50) < 0.0001
FACIT-Fatigue ES = 0.02 ES = 0.92 ES = 1.40 ES = 1.49 < 0.0001
FACIT-Fatigue n = 54 n = 12 n = 6 n = 10 < 0.0001
SF-36
PCS 0.79 (0.42) 6.36 (1.00) 11.38 (1.12) 14.28 (0.77) <0.0001
PCS ES = 0.10 ES = 0.81 ES = 1.44 ES = 1.81 < 0.0001
PCS n = 217 n = 63 n = 42 n = 60 < 0.0001
MCS 0.54 (0.70) 3.33 (1.24) 1.86 (1.70) 9.61 (1.14) < 0.0001
MCS ES = 0.05 ES = 0.30 ES = 0.17 ES = 0.86 < 0.0001
MCS n = 217 n = 63 n = 42 n = 60 < 0.0001
Physical function 0.48 (1.11) 14.82 (1.98) 17.30 (2.90) 25.34 (2.72) < 0.0001
Physical function ES = 0.02 ES = 0.67 ES = 0.79 ES = 1.15 < 0.0001
Physical function n = 222 n = 64 n = 43 n = 60 < 0.0001
Role- physical 5.31 (1.80) 22.66 (4.16) 37.21 (6.30) 55.00 (4.40) < 0.0001
Role- physical ES = 0.18 ES = 0.77 ES = 1.27 ES = 1.88 < 0.0001
Role- physical n = 223 n = 64 n = 43 n = 60 < 0.0001
Bodily pain 3.03 (0.96) 17.50 (2.18) 30.40 (2.97) 41.02 (2.24) < 0.0001
Bodily pain ES = 0.19 ES = 1.11 ES = 1.92 ES = 2.60 < 0.0001
Bodily pain n = 223 n = 64 n = 43 n = 60 < 0.0001
General health -0.12 (0.93) 4.78 (1.84) 13.19 (2.50) 21.40 (2.17) < 0.0001
General health ES = 0.01 ES = 0.24 ES = 0.66 ES = 1.07 < 0.0001
General health n = 221 n = 63 n = 42 n = 60 < 0.0001
Vitality 2.50 (1.07) 13.52 (1.84) 18.49 (2.68) 31.56 (2.36) < 0.0001
Vitality ES = 0.14 ES = 0.77 ES = 1.05 ES = 1.79 < 0.0001
Vitality n = 222 n = 64 n = 43 n = 60 < 0.0001
Social function 1.79 (1.36) 11.91 (2.62) 9.01 (3.36) 27.08 (2.63) < 0.0001
Social function ES = 0.07 ES = 0.49 ES = 0.37 ES = 1.12 < 0.0001
Social function n = 223 n = 64 n = 43 n = 60 < 0.0001
Role- emotional 3.32 (2.88) 13.54 (5.74) 15.50 (7.87) 32.22 (4.95) < 0.0001
Role- emotional ES = 0.08 ES = 0.32 ES = 0.36 ES = 0.76 < 0.0001
Role- emotional n = 221 n = 64 n = 43 n = 60 < 0.0001
Mental health -0.01 (1.09) 5.98 (1.63) 4.23 (2.54) 17.20 (1.77) < 0.0001
Mental health ES = 0.00 ES = 0.32 ES = 0.23 ES = 0.92 < 0.0001
Mental health n = 222 n = 64 n = 43 n = 60 < 0.0001
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in patients with AS. We evaluated the psychometric
characteristics of two instruments – the SF-36 Health
Survey and FACIT-Fatigue – based on a secondary ana-
lysis of blinded clinical trial data from a large sample of
patients with AS. The results indicate that the SF-36 is a
reliable and valid measure of HRQOL in patients with
AS. Although based on a smaller sample size, there is
good evidence supporting the psychometric qualities of
the FACIT-Fatigue subscale in AS patient populations.
The ASQoL is a disease-specific measure of quality of
life with evidence supporting reliability and validity
[14,15]. However, recent qualitative research suggests
that the ASQoL may not cover all important and fre-
quently mentioned patient concerns about HRQOL [43].
We believe that the addition of the SF-36 and FACIT-
Fatigue scales helps provide a more comprehensive
assessment of the main health outcomes important to
patients with AS.
The SF-36 summary scores and subscales (or domains)
were also found to have acceptable reliability and good
evidence of validity in this sample of patients with AS. In
addition, we found a comparable factor solution for the
PCS and MCS using the AS sample. Significant relation-
ships between the SF-36 scores and ASQoL, FACIT-Fati-
gue, and clinical endpoints were observed. We observed
an increase in the correlations among the patient-
reported outcomes at the 12-week assessment, and this
increase was likely attributable to the more restrictive
ranges in patient-reported outcome scores at baseline
because of clinical trial entry criteria. Restricted ranges in
scores may attenuate the correlation coefficients.
The SF-36 scores, especially those measuring physical
function and pain, were responsive to clinical improve-
ments as assessed with the ASAS response criteria. For
example, there was a 5.6-point (SD = 6.6) difference in
PCS scores between ASAS nonresponders and ASAS20
responders, a 10.6-point (SD = 6.2) difference between
nonresponders and ASAS50 responders, and a 13.5-
point (SD = 6.1) difference between nonresponders and
ASAS70 responders. Less consistent findings were
observed for the MCS. ASAS50 and ASAS70 responder
groups achieved greater improvements vs. the non-
responders or ASAS20 responders for measures of phy-
sical and role function, pain, general health, and vitality.
Published clinical trials in AS have found that several
SF-36 subscale scores are responsive to treatment effects
[11,19,21,39-42]. Certainly, 5-point differences or mean
changes in PCS or MCS scores are clinically relevant,
and lesser changes of 2.5 to 3.0 points are likely to be
clinically meaningful.
The AS patients in the current analysis had significant
impairment in health status at baseline, consistent with
previous studies [4,32]. In the current analysis, mean
baseline PCS and MCS scores were 32.6 and 43.4,
respectively. The mean scores for these patients with AS
are considerably lower than mean scores of the general
US population [29], with differences of 1.7 standard
deviation units for the PCS and 0.7 standard deviation
units for the MCS. The SF-36 subscales scores for the
current analysis are also less than those reported by
Dagfinrud and colleagues [4] and Chorus and colleagues
[32]. Therefore, the current analysis provides additional
evidence of the significant impairment in health status
and functioning in AS across multiple domains of physi-
cal and role functions, pain, energy, emotional well-
being, and general health perceptions.
FACIT-Fatigue was also shown to have good reliability
and validity in this sample of patients with AS. This
measure focuses on fatigue-related problems and con-
cerns and was originally developed to assess fatigue in
oncology patients [29,30,44] but has been applied to
other chronic diseases, such as rheumatoid arthritis
[28,45]. In this AS sample, we found reliabilities exceed-
ing 0.80 and statistically significant relationships
between the FACIT-Fatigue and measures of vitality,
physical function, role-physical, social function, and clin-
ical severity.
As expected, the FACIT-Fatigue scores were most clo-
sely related to similar endpoints, such as the SF-36 vitality
score and the BASDAI fatigue item. However, meaningful
associations were observed for the other patient-reported
and clinical outcomes, supporting the validity of the
FACIT-Fatigue. These findings for AS patients support
the psychometric qualities of the FACIT-Fatigue for appli-
cation in clinical studies of other populations with rheu-
matic diseases, such as patients with rheumatoid arthritis
[28,45]. In fact, the mean baseline FACIT-Fatigue scores
observed in these patients with AS were much less than
those observed for patients with rheumatoid arthritis
(mean, 23.9 vs. 29.2) or the general US population [29].
T h e s er e s u l t ss u g g e s tt h a tf a t i g u es h o u l db eaf o c u so f
attention in the treatment of AS.
FACIT-Fatigue was responsive to changes in clinical
status based on the ASAS response criteria. We
observed significant improvements in FACIT-Fatigue
scores, with the greatest mean changes observed for
patients meeting ASAS50 or ASAS70 response criteria.
FACIT-Fatigue scores demonstrated a 9.7-point differ-
ence in improvement between nonresponders and
ASAS20 responders. These differences significantly
exceeded the minimum clinically important difference of
3 to 4 points validated for patients with rheumatoid
arthritis [28]. For AS, differences of 4 to 5 points in
FACIT-Fatigue scores may be clinically meaningful;
however, further confirmation is needed.
The results of these psychometric analyses are limited
to patients participating in one of these two clinical
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Page 9 of 11trials, and may not be generalizable to all patients with
AS. However, we propose that, based on the strengths
of the secondary analysis, including comparative clinical
measures, a well-defined patient population, and longi-
tudinal data all provide good evidence supporting the
psychometric characteristics of the SF-36 and FACIT-
Fatigue for AS patients.
Conclusions
In summary, our analysis provides additional evidence
supporting the reliability and validity of the SF-36 and
FACIT-Fatigue in patients with AS. The SF-36 has been
widely used in rheumatoid arthritis and AS clinical
trials, and this analysis demonstrated that this generic
health status measure is psychometrically sound and
responsive in AS. As AS has broad and extensive
impacts on HRQOL, comprehensive measures of patient
outcomes are necessary for evaluating the effectiveness
of new treatments. The FACIT-Fatigue has not been
widely used in AS studies. However, we have provided
evidence supporting its validity and, more importantly,
its responsiveness. Based on these findings, a PRO bat-
tery consisting of the ASQoL, SF-36, and FACIT-Fatigue
scale represents a useful, valid, and responsive approach
to fully capturing effects of treatment on the health out-
comes of AS patients. These PRO data, combined with
clinical endpoints, may also assist physicians and their
patients in determining the most effective treatments for
AS.
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